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Summary It is generally accepted that the spine is the site of predilection for retinoid-induced i
abnormalities. However, the reported prevalence of skeletal problems varies widely. To investigate 
the frequency and severity of retinoid-induced spinal abnormalities, all records of patients who  
underwent spinal radiographs at the request of the department of dermatology between 198 3 and 
199 3 were reviewed. This group of 1 35 patients comprised the total population of retinoid-treated 
patients and those patients who were investigated for possible future retinoid treatment. The mean 
treatment period in the total group was 30 months and the mean cumulative dose of retinoid was 
31 g. In 50 patients the treatment period was ^  24 months with 30 patients being treated for more 
than 48  months. Baseline radiographs were available from 26 patients and these were comp, 
with the most recent X-rays during treatment. The mean treatment period in this ‘prospective group’ 
was 2 5 months and the mean cumulative dose of retinoid was 25 g.
The prevalence of diffuse idiopathic skeletal hyperostosis (DISH), degenerative changes and 
osteoporosis in the total group was respectively 16%, 53% and 29%. There was no statistically 
significant relation between the duration of treatment or the cumulative dose and the prevalence or
of DISH, degenerative changes and osteoporosis. Only the age of the t  \  1 1
significantly related to the frequency and severity of skeletal abnormalities. In the ‘prospective 
group', again, no important changes were observed between the radiographs at baseline and during
In this study no relation whatsoever between spinal abnormalities and prolonged oral retinoid
established. The performance of annual routine spinal radiographs during
retinoid treatment is not necessary in our opinion. Additional controlled and prospective studies on 
spinal and extraspinal skeletal abnormalities are required to develop definitive screening guidelines 
for patients submitted to long-term retinoid treatment.
71
Table 1. Skeletal abnormalities following treatment with etretinate and acitretin in adults. Review of the literature (n ^  5)
Authors n
Study
design3 Methodb Retinoidc
Mean age 
(years)
Mean treatment 
period (months)
Mean dailv 
dose (mg/kg )
% with skeletal abnormalities 
Spinal Extraspinal Total
Wilson et cd/ (1988) 23 R R/S E 42 46 0-5 39 26 57
Montag et al.s (1988) 11 R R E 25 75 3 2 mg/day 9 18 18
Halkier-Sorensen et al.9 (1989) 90 R R E 50 29 0-6 49
Gerber et al.10 (1984)
patients 37 RC R E 41 > 24 0-6 14e
controls 72 42
DiGiovanna et id.11 (1986)
patients 38 RC R E 44 60 0-8 29 84
00
controls 55 27
Melnik et al.12 (1987)
patients 8 RC R E 49 49 38mg/day 100 75 100e
controls 8 75 25 75
Zeiger et al.13 (1990)
patients 46d RC R E 50 53 0-5 41e
controls 43 56 30
Gilbert et al.u  (1986) 8 P R E 51 11 0-5-1-2 0 0 0
Kilcoyne et al.1* (1988) 240 P R A 12-24 10-75 mg/day 5
Török et al.16 (1989) 15 P S E 33 4 0-7-1*0 0
Morkrtai.1' (1992) 45 P R/S A 48 24 0-5 13 11 24
Hohl et al.18 (1992) 16 P R A 46 11 0-4 6 0 6
Kullavanijaya et al.19 (1993) 16 P R A 28 12 0-4 63
a R  — retrospective; RC =  retrospective controlled: P =  prospective. 
b R =  radiography; S =  scintigraphy.
CE = etretinate; A =  acitretin.
d 39 patients etretinate; 4 patients isotretinoin; 3 patients arothenoidethylester (Ro—6298). 
e Difference patients—controls not significant.
r
Difference patients— controls significant (P < 0-001).
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dose and the age of the patient. Pretreatment radio­
graphs were available in 26 patients and these were 
compared with the most recent X-rays during treatment.
Methods
The records of all patients who underwent spinal 
radiographs on request of the department of dermatol­
ogy during the period 1983-93 were reviewed. Radio- 
graphic examination of the spine is part of our protocol 
for oral retinoid treatment. Patients who underwent 
pretreatment screening were also included in the study. 
The duration of treatment and the cumulative dose of 
etretinate and acitretin were calculated in each patient. 
For all calculations we chose as the reference point the 
time of the most recent radiographic survey. From the 
total group a ‘prospective group’ was identified who had 
had pretreatment radiographs as well as one or more 
X-ray surveys during retinoid therapy and who had 
had a minimal treatment period of 9 months.
Both the available pretreatment radiographs and the 
most recent radiographs of each patient 
posterior as well as lateral views) were evaluated by 
the same radiologist (JAML). The radiographs were 
reviewed in arbitrary sequence and in chronological 
order for each patient. The radiologist was unaware of 
details from the patient’s records. The vertebral levels
-Thl2 and L I-S I of all radiographs wereC3-C7,
investigated for osteophytes (small, medium or large), 
syndesmophytes (1/3, 2/3 or 3/3 bridging), osteoporo-
al discs 'sis, narrowing of the 
calcification. Triangular outgrowths located several 
millimetres from the edge of the vertebral bodies were 
defined as osteophytes and vertical
from the edge of one vertebral body to the next were
\s.“° DISH was diagnosedO
when the spinal n
rior aspect of at least three vertebral bodies, a relative
preservé of bra! disc height in the involved
ibsenee of osseous fusions.
inte r ver t e b r a 1 dis c s
vertebral segment and 
Osteophytes and narrowing of 
were defined as degenerative elu 
no’ classification of DISH, 
osteoporosis, total severity scores for 
erative changes were defined for each reviewed spinal
of DISH (0-84
yes or 
changes and 
in d
. To
ÎSS
one-third
vertebral level and, when more than two-thirds of the 
intervertebral disc height was involved, the score was 3 
points per vertebral level. Ligament calcification was 
scored with 1 point per vertebral level. To compute the 
severity score of degenerative changes (0-84 points), 
small, medium or large osteophytes were scored with 
respectively 1, 2 or 3 points per vertebral level and disc 
narrowing was scored with 1 point per vertebral level.
:osis was assessed only as present or absent. A 
severity score was not used, as plain radiography is
* method to evi
■£<
an me
ity of
scores of DISH, degenerative changes and osteoporosis 
were assessed and related to duration of retinoid treat-
ind age of the patients. For the 
‘prospective group’ the prevalence and severity scores of
alities and osteoporosis in 
the pretreatment situation were compared with the 
most recent radiographs during retinoid treatment.
of DISH,Possible dependencies of the
degenerative changes and osteoporosis on the one hand 
on duration of treatment, cumulative dose and age on the 
other hand were investigated using stepwise logistic 
regression with the latter three parameters as indepen­
dent variables. The relationship between the severity 
scores of DISH and degenerative changes and duration
age wasof treatment, cumulative dose 
using Spearman’s rank correlation
Results
The spinal t ! of 135 patients (81 men and 54
women) were s 
4 6
. The mean age of the patients was 
population consisted of 77 patients
chronic
period in the total group was 30 you* m
c
*
C
n ri 3 i l  In
treatment period was ^  
patients were treated for more than 48
30
Prevalence of diffuse idiopathic skeletal hyperostosis, degen-
The ï
€
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Total
n J6 29 23 32 15 135
DISH (%) 3 3 9 38 33 16
Degenerative changes (%) 19 52 52 81 80 53
Osteoporosis (%) 14 21 35 38 53 29
Table 2. Incidence of spinal abnormalities in 
relation to age of the patients
DISH, diffuse idiopathic skeletal hyperostosis.
changes and osteoporosis for different age classes 
(Table 2).
severity scores of DISH (Fig. 1) and degenerative 
changes and the duration of treatment or the cumula­
tive dose. The correlation coefficients of the severity 
scores of DISH and degenerative changes with age,
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Figure 1. Severity score : skeletal hyperostosis (DISI 1) in relation to duration of retinoid treatment.
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however, appeared to be int: I 0-39
(P < 0-01) lor DISH and r =  0*6.1 (P < 0-01) for degen­
erative changes.
provided the opportunity to relate the frequency and 
severity of the various spinal abnormali 
duration of treatment, the cumulative dose and the
‘Prospective group’
In the ‘prospective group’ (n — 26), the mean duration 
of treatment was 25 months (9-6.1 months). The mean
se was 25g (6'6-61*2g). Before treat­
ment; two of 26 patients had DISII vs. four of 26 patients
patients
treatment had treatment periods of 14 
and 29 months. Their severity score was only 4 points
5H s e points). i re
treatment 14 of 2 
changes; during tret
had
15 of 26 patients. Osteo-
age of the patients. As this could be a possible reason 
lor bias, it is important that not a single patient was 
excluded from retinoid treatment because of pre-exist-
rmalities. The mean age of the patients 
! duration of treatment showed a rather 
homogeneous distribution and all patients suffered from
ing skeletal i 
in relation to
srs of kératinisation. Thesevere psoriasis or
xtensive (135 patients), especially in 
available reports in the literature 
s a 'prospective' sample of 26 
patients. A mean duration of treatment of 30 months 
and a mean cumul 
50 patients were tree
31 g are c 
for more than 24 months and
porosis was diagnosed in nine of 26 patients before 
treatment and in 10 of 26 patients during treatment. 
These differences were too small to be meaningfully 
analysed statistically.
The two patients with DISH before treatment did not
30 patients for more than 48 months. Another advan­
tage of this study is the fact that the results concern all 
retinoids used by the patients, so that possible bias 
induced by retinoid treatment in the past is avoided. 
The conclusion which is reached from the data presented
any
period 10 and 12 months). Three of the 14 patients 
with degenerative changes before treatment showed a
(1-2 points) of the severity score
14, 19 and 5 3during tret 
months).
in this communicati and clear. There was no 
relation whatsoever between the duration of retinoid 
treatment or the cumulative dose and the prevalence 
and severity of DISH, degenerative changes and osteo­
porosis. The only significant variable in this respect was 
the age of patients. Owing to the inconsistency of 
iteria used in the literature, it is not
Many reports have appeared in the recent literature on
retinoid-i I
no consensus has
malities (T;
reac
1).
«lia 19
o n
frequency and magnitude of these side-effects. Most of
communications are anecdotal, the population
inantly uncontrolled, and prospec-\s are pre
to provide a c 
reported by
These
of our results
s (Tabic 1 ).
’C IS. h ii s
draw
conclusions, but we would like to suggest that spinal 
abnormalities due to oral retinoid treatment only occur 
sporadically in n
described as ‘an extremely common’ entity in the gen­
eral population and spinal < \s, ae
live studies on prolonged treatment with ora 
are not available. A major problem in these studies Is
rentiation of ret inoid-induced from age-induced
changes. The reported prevalence of DISH in the 
al population varies from 2-6 to 28%." 11 is 
complicated to conduct an extensive placebo
,  isstudy for practical and e al reasons.
Furthermore, there is no consensus on the definitions
of the and severity of retinoid-induced spinal
in the literature, are probably more a normal variation 
than a complication of retinoid treatment.
There is no consensus on the guidelines for routine 
surveillance of patients during prolonged retinoid treat­
ment, recommendations in the literature diverge from
all ’ to pretrealment andn o -ray scree at
annual scree
W ) ^  ) y
of spinal areas/’ '~f Several 
authors recommend additional screening of ex tra spinal 
areas.5,29 The present study does not lend support to the
abnormalities. In the present study we défini
lions that are now generally accepted in the radiological
design of the present s is retro-
performance of annual routine spinal 
during retinoid treatment. It is important to ask lor 
skeletal pains and mobility restriction on a regular basis
% f 'c , c •er it ics of our
population and of those patients who
oral reti treatment and to focus on
spinal and extraspinal regions.
it)
went pretr* screening. This approach 4C prospective s *
i(‘i 19 l)f> British Association of Dermatologists, British journal o fDer . 71 7h
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required to develop definitive screening guidelines for 
patients submitted to long-term oral retinoid treatment. 
Further investigations should be focused on the basic 
mechanisms and specific locations of retinoid-induced 
bone changes and on defining high-risk patients in this 
respect.
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